Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

Geoffrey Y. Ku, Gilberto De Lima Lopes, Alex Y Chang

Research output: Contribution to journalArticle

Abstract

Aims: Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub-optimal and toxic. Methods: We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin. Results: Of the five patients, four had cirrhosis; two patients had Child-Pugh A cirrhosis, while one each had Child-Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50% in alpha-fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease. Conclusion: These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.

Original languageEnglish (US)
Pages (from-to)174-179
Number of pages6
JournalAsia-Pacific Journal of Clinical Oncology
Volume7
Issue number2
DOIs
StatePublished - Jun 2011

Fingerprint

oxaliplatin
Liver Neoplasms
Doxorubicin
Fibrosis
Poisons
alpha-Fetoproteins
liposomal doxorubicin
Bevacizumab

Keywords

  • Bevacizumab
  • Chemotherapy
  • Doxorubicin
  • Hepatocellular carcinoma
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology

Cite this

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer : A case series. / Ku, Geoffrey Y.; De Lima Lopes, Gilberto; Chang, Alex Y.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 7, No. 2, 06.2011, p. 174-179.

Research output: Contribution to journalArticle

@article{128605a57dcc4220ac9e2e9b1840e090,
title = "Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series",
abstract = "Aims: Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub-optimal and toxic. Methods: We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin. Results: Of the five patients, four had cirrhosis; two patients had Child-Pugh A cirrhosis, while one each had Child-Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50{\%} in alpha-fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease. Conclusion: These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.",
keywords = "Bevacizumab, Chemotherapy, Doxorubicin, Hepatocellular carcinoma, Oxaliplatin",
author = "Ku, {Geoffrey Y.} and {De Lima Lopes}, Gilberto and Chang, {Alex Y}",
year = "2011",
month = "6",
doi = "10.1111/j.1743-7563.2010.01345.x",
language = "English (US)",
volume = "7",
pages = "174--179",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer

T2 - A case series

AU - Ku, Geoffrey Y.

AU - De Lima Lopes, Gilberto

AU - Chang, Alex Y

PY - 2011/6

Y1 - 2011/6

N2 - Aims: Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub-optimal and toxic. Methods: We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin. Results: Of the five patients, four had cirrhosis; two patients had Child-Pugh A cirrhosis, while one each had Child-Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50% in alpha-fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease. Conclusion: These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.

AB - Aims: Despite the emergence of sorafenib as the standard treatment for patients with advanced hepatocellular cancer (HCC), therapy remains sub-optimal and toxic. Methods: We report on five patients with advanced HCC treated with bevacizumab, oxaliplatin and doxorubicin or liposomal doxorubicin. Results: Of the five patients, four had cirrhosis; two patients had Child-Pugh A cirrhosis, while one each had Child-Pugh B and C cirrhosis. Grade 3/4 toxicity was uncommon. Four patients had a decrease of ≥50% in alpha-fetoprotein levels following therapy and one patient each had a radiographic complete response and stable disease. Conclusion: These data add to the growing phase II data that bevacizumab-containing regimens are active in advanced HCC patients. Further evaluation of regimens containing bevacizumab with oxaliplatin and/or doxorubicin may be warranted.

KW - Bevacizumab

KW - Chemotherapy

KW - Doxorubicin

KW - Hepatocellular carcinoma

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=79956080087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956080087&partnerID=8YFLogxK

U2 - 10.1111/j.1743-7563.2010.01345.x

DO - 10.1111/j.1743-7563.2010.01345.x

M3 - Article

C2 - 21585698

AN - SCOPUS:79956080087

VL - 7

SP - 174

EP - 179

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 2

ER -